• The company has made giant strides in putting its financials in order, getting rid of almost $1B in debt and its net debt has been all but eliminated.
• We believe more is to come as the company’s all-digital business model is very scalable.
• There are some risks, the company will have to start paying royalties on its top-selling drug and there might still be some legal risks from their opioid days.
• Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »

Assertio’s Phenomenal Turnaround (NASDAQ:ASRT)